# Optimizing Response in Psychosis Study

> **NCT00314327** · PHASE4 · TERMINATED · sponsor: **Northwell Health** · enrollment: 1 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorder
- Psychotic Disorder Not Otherwise Specified

## Interventions

- **DRUG:** long-acting injectable risperidone

## Key facts

- **NCT ID:** NCT00314327
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Recruitment for the study was limited.
- **Last updated:** 2018-05-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00314327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00314327, "Optimizing Response in Psychosis Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00314327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*